Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Clinical trial NCT03867084 · COMPLETED
Trial details
- NCT number
- NCT03867084
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-28
- Primary completion
- 2025-03-20
- Enrollment
- 959
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.